[1] Weir HM,Bradbury RH,Lawson M,et al.AZD9496:an oral estrogen receptor inhibitor that blocks the growth of er-positive and esr1-mutant breast tumors in preclinical models[J].Cancer Res,2016,76(11):3307-3318.
[2] Vanderstichele A,Neven P,Vergote I.Combined modality adjuvant therapy for high-risk endometrial cancer[J].Lancet Oncol,2016,17(8):1029-1030.
[3] Rose PG.Endometrial carcinoma[J].N Engl J Med,1996,335(9):640-649.
[4] Morice P,Leary A,Creutzberg C,et al.Endometrial cancer[J].Lancet,2016,387(10023):1094-1108.
[5] Poorolajal J,Nafissi N,Akbari ME,et al.Breast cancer survival analysis based on immunohistochemistry subtypes (er/pr/her2):a retrospective cohort study[J].Arch Iran Med,2016,19(10):680-686.
[6] Sieh W,Kobel M,Longacre TA,et al.Hormone-receptor expression and ovarian cancer survival:an ovarian tumor tissue analysis consortium study[J].Lancet Oncol,2013,14(9):853-862.
[7] Arafa M,Somja J,Dehan P,Kridelka F,et al.Current concepts in the pathology and epigenetics of endometrial carcinoma[J].Pathology,2010,42(7):613-617. |
2018, Vol. 35 
